Koers HLS Therapeutics Inc Toronto S.E.
Aandelen
AM
CA05328X1015
Farmaceutische producten
Omzet 2024 * | 64,08 mln. 87,58 mln. 59,93 mln. | Omzet 2025 * | 73,43 mln. 100 mln. 68,68 mln. | Marktkapitalisatie | 108 mln. 148 mln. 101 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -20 mln. -27,34 mln. -18,71 mln. | Nettowinst (verlies) 2025 * | -17 mln. -23,24 mln. -15,9 mln. | EV/omzet 2024 * | 1,69 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,47 x |
K/w-verhouding 2024 * |
-6,33
x | K/w-verhouding 2025 * |
-9,44
x | Werknemers | - |
Dividendrendement 2024 * |
4,36% | Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,51% |
Recentste transcriptie over HLS Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 56 | 01-05-23 |
John Hanna
DFI | Director of Finance/CFO | - | 22-06-23 |
Ryan Lennox
CMP | Compliance Officer | 43 | 07-05-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Welborn
CHM | Chairman | 46 | 18-06-21 |
Laura Brege
BRD | Director/Board Member | 66 | 21-03-19 |
John Hanna
DFI | Director of Finance/CFO | - | 22-06-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,35% | 71,39 mld. | |
+2,39% | 25,1 mld. | |
+5,38% | 8,59 mld. | |
+6,69% | 8,19 mld. | |
-20,96% | 7,91 mld. | |
+0,49% | 4,54 mld. | |
+17,12% | 4,31 mld. | |
-3,38% | 3,93 mld. | |
-2,61% | 3,86 mld. |